ABZA Abzena

TIDMABZA

RNS Number : 4087P

Abzena PLC

29 May 2018

Abzena plc

Notice of full year results

Cambridge, UK, 29 May 2018 - Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, will publish its full year results for the year to 31 March 2018 on Monday, 4 June 2018.

A presentation for analysts will be held at 09:30am on 4 June 2018 at the offices of Instinctif Partners (65 Gresham Street, London EC2V 7NQ).

-Ends-

Enquiries:

 
   Abzena plc 
    John Burt, Chief Executive 
    Officer Julian Smith, Chief 
    Financial Officer                  +44 1223 903498 
   Numis (Nominated Adviser and 
    Broker) 
    Clare Terlouw / James Black        +44 20 7260 
    / Paul Gillam                       1000 
   N+1 Singer (Joint Broker)           +44 20 7496 
    Aubrey Powell / Liz Yong            3000 
   Instinctif Partners                 +44 20 7457 
    Melanie Toyne Sewell / Rozi         2020 
    Morris / Alex Shaw                  abzena@instinctif.com 
 

Notes to Editors

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'ABZENA Inside' products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

-- Biology research services, including immunogenicity assessment of candidate biopharmaceutical products and bioassay development;

-- Protein engineering to optimise biopharmaceutical product candidates, including humanization and deimmunization of antibodies and other therapeutic proteins;

   --     Cell line development for the manufacture of recombinant proteins and antibodies; 

-- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and other recombinant proteins for preclinical and clinical studies;

-- Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

   --     Proprietary site-specific conjugation technologies and novel payloads for ADC development; 
   --     GMP manufacturer of ADC linkers, payloads & combined linker-payloads; and. 
   --     GMP analytical services for biopharmaceutical manufacturing projects 

For more information, please see www.abzena.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORDMGZKVKVGRZM

(END) Dow Jones Newswires

May 29, 2018 04:00 ET (08:00 GMT)

Abzena (LSE:ABZA)
Historical Stock Chart
From Mar 2024 to Apr 2024

Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2023 to Apr 2024